We developed a model small-molecule drug conjugate (SMDC) that employed doxorubicin
as a representative chemotherapeutic targeted to the cell membrane biomarker PSMA …

Small-molecule drug conjugates (SMDCs) are compounds in which a therapeutic payload is
conjugated to a targeting vector, for specific delivery to the tumor site. This promising …

Herein, we report the modular synthesis and evaluation of a prostate-specific membrane
antigen (PSMA) targeted small molecule drug conjugate (SMDC) carrying the …

Prostate-specific membrane antigen (PSMA) provides an attractive target for the
development of targeted chemotherapeutics for prostate cancer. We have designed and …

Most patients with advanced prostate cancer (PCa) will develop metastatic castration-
resistant prostate cancer (mCRPC) after androgen deprivation therapy, at this time the tumor …

This work describes the enhancement of a novel antitumor therapeutic platform that
combines advantages from small-molecule drug conjugates (SMDCs) and antibody drug …

Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II
(GCPII), has recently emerged as a prominent biomarker of prostate cancer (PC) and as an …

Targeting therapy is a concept that has gained significant importance in recent years,
especially in oncology. The severe dose-limiting side effects of chemotherapy necessitate …

New targeted chemotherapeutics are urgently needed to minimize off-target toxicity and
reduce the high-mortality rate associated with metastatic prostate cancer. Herein, we report …

Simple Summary Currently, there is no effective treatment that can cure metastatic prostate
cancer. Various pros-tate specific membrane antigen (PSMA)-targeted radioimaging and …